These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16291086)
21. IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells. Pitulis N; Papageorgiou E; Tenta R; Lembessis P; Koutsilieris M Anticancer Res; 2009 Jun; 29(6):2331-7. PubMed ID: 19528499 [TBL] [Abstract][Full Text] [Related]
22. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. Edwards J; Krishna NS; Mukherjee R; Bartlett JM J Pathol; 2004 Oct; 204(2):153-8. PubMed ID: 15378488 [TBL] [Abstract][Full Text] [Related]
23. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Bajo AM; Schally AV; Krupa M; Hebert F; Groot K; Szepeshazi K Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3836-41. PubMed ID: 11891317 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Kanashiro CA; Schally AV; Groot K; Armatis P; Bernardino AL; Varga JL Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15836-41. PubMed ID: 14660794 [TBL] [Abstract][Full Text] [Related]
25. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Chen SY; Cai C; Fisher CJ; Zheng Z; Omwancha J; Hsieh CL; Shemshedini L Oncogene; 2006 Nov; 25(54):7212-23. PubMed ID: 16732317 [TBL] [Abstract][Full Text] [Related]
26. [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro]. Zhang H; Lü JJ; Gao QZ; Zhang J Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):382-5. PubMed ID: 16638347 [TBL] [Abstract][Full Text] [Related]
27. New treatment approaches for prostate cancer based on peptide analogues. Stangelberger A; Schally AV; Djavan B Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818 [TBL] [Abstract][Full Text] [Related]
28. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142 [TBL] [Abstract][Full Text] [Related]
29. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone. Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196 [TBL] [Abstract][Full Text] [Related]
31. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257 [TBL] [Abstract][Full Text] [Related]
32. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state. Oka H; Chatani Y; Kohno M; Kawakita M; Ogawa O Int J Urol; 2005 Oct; 12(10):899-905. PubMed ID: 16323984 [TBL] [Abstract][Full Text] [Related]
33. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2. Chang HL; Wu YC; Su JH; Yeh YT; Yuan SS J Pharmacol Exp Ther; 2008 Jun; 325(3):841-9. PubMed ID: 18337475 [TBL] [Abstract][Full Text] [Related]
34. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095). Sotomayor S; Muñoz-Moreno L; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM Int J Cancer; 2010 Oct; 127(8):1813-22. PubMed ID: 20099275 [TBL] [Abstract][Full Text] [Related]
35. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Köster F; Engel JB; Schally AV; Hönig A; Schröer A; Seitz S; Hohla F; Ortmann O; Diedrich K; Buchholz S Breast Cancer Res Treat; 2009 Jul; 116(2):273-9. PubMed ID: 18629632 [TBL] [Abstract][Full Text] [Related]
36. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Szepeshazi K; Schally AV; Groot K; Armatis P; Halmos G; Herbert F; Szende B; Varga JL; Zarandi M Br J Cancer; 2000 May; 82(10):1724-31. PubMed ID: 10817510 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist. Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435 [TBL] [Abstract][Full Text] [Related]
38. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Paone A; Starace D; Galli R; Padula F; De Cesaris P; Filippini A; Ziparo E; Riccioli A Carcinogenesis; 2008 Jul; 29(7):1334-42. PubMed ID: 18566014 [TBL] [Abstract][Full Text] [Related]
39. Protein kinase C-zeta activation markedly enhances beta-cell proliferation: an essential role in growth factor mediated beta-cell mitogenesis. Vasavada RC; Wang L; Fujinaka Y; Takane KK; Rosa TC; Mellado-Gil JM; Friedman PA; Garcia-Ocaña A Diabetes; 2007 Nov; 56(11):2732-43. PubMed ID: 17686945 [TBL] [Abstract][Full Text] [Related]
40. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Letsch M; Schally AV; Busto R; Bajo AM; Varga JL Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]